Study summary · research use only
Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review, addressing human type 2 diabetes therapeutics, summarizes research on vasoactive intestinal peptide (VIP), a 28-amino-acid peptide, and its VPAC2 receptor. It describes VIP as stimulating glucose-dependent insulin secretion, particularly via VPAC2 receptor binding, and promoting islet β-cell proliferation through the forkhead box M1 pathway, though the abstract notes the specific molecular mechanism remains to be studied. It notes VIP's clinical use is limited by its short half-life and wide bodily distribution, and describes the development of VPAC2-selective agonists as candidate hypoglycemic drugs based on VIP-VPAC2 binding properties. The review covers VIP's physiological role in glucose homeostasis and discusses the potential therapeutic value of VPAC2-selective agonists for type 2 diabetes.
Abstract
Owing to the increasing prevalence of type 2 diabetes, the development of novel hypoglycemic drugs has become a research hotspot, with the ultimate goal of developing therapeutic drugs that stimulate glucose-induced insulin secretion without inducing hypoglycemia. Vasoactive intestinal peptide (VIP), a 28-amino-acid peptide, can stimulate glucose-dependent insulin secretion, particularly by binding to VPAC2 receptors. VIP also promotes islet β-cell proliferation through the forkhead box M1 pathway, but the specific molecular mechanism remains to be studied. The clinical application of VIP is limited because of its short half-life and wide distribution in the human body. Based on the binding properties of VIP and VPAC2 receptors, VPAC2-selective agonists have been developed to serve as novel hypoglycemic drugs. This review summarizes the physiological significance of VIP in glucose homeostasis and the potential therapeutic value of VPAC2-selective agonists in type 2 diabetes.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.